Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib in Poor Performance Status NSCLC with EGFR Mutations
NCT02695290Phase 4Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2016
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of afatinib in non-small cell lung cancer (NSCLC), sponsored by Boehringer Ingelheim. Started Mar 2016; status: terminated.
02
Drugs
afatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02695290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02695290.